A Multicenter, Single-Arm, Phase II Trial of RC48-ADC Combined with Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 (PRaG3.0 regimen) for the Treatment of HER2-Expressing Advanced Solid Tumors

被引：0
|
作者：
Xu, M. [1 ]
Kong, Y. [1 ]
Xing, P. [1 ]
Chen, R. [2 ]
Ma, Y. [1 ]
Shan, C. [2 ]
LiYuan, Z. [3 ]
机构：
[1] Second Affiliated Hosp Soochow Univ, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
[2] Second Affiliated Hosp Soochow Univ, Suzhou, Peoples R China
[3] Soochow Univ, Inst Radiotherapy & Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2957
引用
收藏
页码：E428 / E428
页数：1
相关论文
共 25 条
  • [21] First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
    Mark, Michael Thomas
    Froesch, Patrizia
    Gysel, Katrin
    Rothschild, Sacha
    Addeo, Alfredo
    Ackermann, Christoph J.
    Chiquet, Sabrina
    Schneider, Martina
    Ribi, Karin
    Maranta, Angela Fischer
    Bastian, Sara
    Von Moos, Roger Anton Fredy
    Joerger, Markus
    Fruh, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
    Mark, M.
    Froesch, P.
    Gysel, K.
    Rothschild, S.
    Addeo, A.
    Ackermann, C.
    Chiquet, S.
    Schneider, M.
    Ribi, K.
    Fischer, A.
    Bastian, S.
    von Moos, R.
    Joerger, M.
    Frueh, M.
    SWISS MEDICAL WEEKLY, 2023, 153 : 7S - 7S
  • [23] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
    Li, Ning
    Deng, Wen-Ying
    Ma, Yi-Jie
    Bie, Liang-Yu
    Zhang, Chi
    Wei, Chen
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 367 - 367
  • [25] First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
    Mark, Michael
    Froesch, Patrizia
    Gysel, Katrin
    Rothschild, Sacha I.
    Addeo, Alfredo
    Ackermann, Christoph J.
    Chiquet, Sabrina
    Schneider, Martina
    Ribi, Karin
    Maranta, Angela Fischer
    Bastian, Sara
    von Moos, Roger
    Joerger, Markus
    Frueh, Martin
    EUROPEAN JOURNAL OF CANCER, 2024, 200
123